NanoViricides, Inc. (the "Company") announced today that it has retained Id3A, LLC (“Id3A”), as the architect for its laboratory and cGMP pilot production facility project. As previously announced, this facility will be built by renovating an existing 18,000 sq. ft. light manufacturing plant on a 4.2 acre lot in Shelton, CT. Ms. Kathyann Cowles, AIA, will serve as the Principal Architect for the project. Id3A recently began working with the Company for the architecture portion and now the Company has formally engaged Id3A as the architects for this project.
As Twelfth Night approaches and the Christmas decorations start to look increasingly congruous as the last crumbs of cake are swept away and the remnants of the turkey have finally been consumed, there is the perennial question as to what to do with the tree. Research published in the International Journal of Biomedical Nanoscience and Nanotechnology suggests that the needles of the plant Pseudotsuga menziesii, commonly known as the Douglas fir could be used to sterilize nano devices destined for medical applications.
President Barack Obama named University of Missouri researcher M. Frederick Hawthorne as recipient of the National Medal of Science, the highest honor bestowed by the country to scientists. Hawthorne is the director of the International Institute of Nano and Molecular Medicine at the University of Missouri, as well as Curators' Distinguished Professor of Chemistry and Radiology.
Tufts University School of Engineering researchers have developed a novel method for fabricating collagen structures that maintains the collagen's natural strength and fiber structure, making it useful for a number of biomedical applications.
Pedro Valencia, who earned his PhD in chemical engineering at MIT in November, was named in Forbes magazine's 2012 list of the top 30 rising stars in science and health.
NanoViricides, Inc. (the "Company"), announced today that it has received the final tranche of $2.5M from Seaside 88, LP (“Seaside”), thereby completing the total of a $5M financing. This raise, and the receipt of the initial $2.5M tranche, was previously announced on June 29, 2012.
Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat debilitating diseases, announced today that it has secured a $16 million Series B financing. Blend is pioneering an integrative model for discovering novel molecular entities with new mechanisms of action purposely designed for Blend’s proprietary nanoparticles. By synergistically developing both the molecule and the nanoparticle together, Blend can make medicines more targeted, more effective and more tolerable.
Taiwan’s National Cheng Kung University (NCKU) and America’s Argonne National Laboratory (ANL), which have enjoyed close collaborative ties for years, are planning to jointly compete for an International Research-Intensive Centers for Excellence (I-RiCE) center on nanocarbon technology.
Sirnaomics, Inc. announced today that the company has made a major breakthrough in its novel small interfering RNA (siRNA) therapeutic product against human papillomavirus (HPV) infection and cervical cancer which was presented by Dr. Alan Lu , Executive Vice President of Sirnaomics, in the 28th International Papillomavirus Conference held in San Juan, Puerto Rico from Nov 30th to Dec 6th, 2012.
MagForce AG (Frankfurt, Xetra: MF6), a leading medical device company in the field of nanomedicine with a focus on oncology, today announced that the Company, with the approval of the Supervisory Board, has resolved a restructuring plan to safeguard MagForce's long-term existence.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.